Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABT Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

CHF114.72

▲(8.22%Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is CHF114.72 with a high forecast of CHF127.32 and a low forecast of CHF101.70. The average price target represents a 8.22% change from the last price of CHF106.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"89":"CHF89","128":"CHF128","98.75":"CHF98.8","108.5":"CHF108.5","118.25":"CHF118.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":127.32243318,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF127.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":114.7183130652,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF114.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.69779254,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF101.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[89,98.75,108.5,118.25,128],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106,107.6401871676923,109.28037433538462,110.92056150307693,112.56074867076923,114.20093583846153,115.84112300615385,117.48131017384615,119.12149734153846,120.76168450923078,122.40187167692308,124.04205884461538,125.6822460123077,{"y":127.32243318,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106,106.67063946655385,107.34127893310769,108.01191839966154,108.68255786621538,109.35319733276923,110.02383679932308,110.69447626587692,111.36511573243077,112.03575519898462,112.70639466553845,113.3770341320923,114.04767359864614,{"y":114.7183130652,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106,105.66906096461538,105.33812192923077,105.00718289384615,104.67624385846153,104.34530482307692,104.0143657876923,103.6834267523077,103.35248771692308,103.02154868153846,102.69060964615385,102.35967061076923,102.02873157538461,{"y":101.69779254,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.099,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.099,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.554,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.584,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.061,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.531,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.531,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.531,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.066,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.066,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.066,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF127.32

Average Price TargetCHF114.72

Lowest Price TargetCHF101.70

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Suraj KaliaOppenheimer

Oppenheimer

CHF114.59

Buy

8.10%

Upside

Reiterated

06/18/25

Abbott Laboratories (ABT) Gets a Buy from Oppenheimer

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

06/18/25

Citi Keeps Their Buy Rating on Abbott Laboratories (ABT)

Mike KratkyLeerink Partners

Leerink Partners

CHF117.04

Hold

10.42%

Upside

Initiated

06/16/25

Abbott Laboratories (ABT) Receives a Hold from Leerink Partners

Larry BiegelsenWells Fargo

Wells Fargo

CHF120.32

Buy

13.51%

Upside

Reiterated

06/09/25

Wells Fargo Remains a Buy on Abbott Laboratories (ABT)

Josh JenningsTD Cowen

TD Cowen

CHF118.68

Buy

11.96%

Upside

Reiterated

06/09/25

TD Cowen Remains a Buy on Abbott Laboratories (ABT)

Rick WiseStifel Nicolaus

Stifel Nicolaus

CHF110.49→CHF118.68

Buy

11.96%

Upside

Reiterated

05/27/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)

Matt MiksicBarclays

Barclays

CHF130.14

Buy

22.77%

Upside

Reiterated

05/20/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Alcon (NYSE: ALC)

David ToungArgus Research

Argus Research

CHF122.77

Buy

15.82%

Upside

Reiterated

04/21/25

Argus Research Remains a Buy on Abbott Laboratories (ABT)

Jayson BedfordRaymond James

Raymond James

CHF108.04→CHF116.22

Buy

9.64%

Upside

Reiterated

04/17/25

Abbott price target raised to $142 from $132 at Raymond JamesAbbott price target raised to $142 from $132 at Raymond James

Adam MaederPiper Sandler

Piper Sandler

CHF108.86→CHF118.68

Buy

11.96%

Upside

Reiterated

04/17/25

Abbott price target raised to $145 from $133 at Piper SandlerAbbott price target raised to $145 from $133 at Piper Sandler

Danielle AntalffyUBS

UBS

CHF121.13

Buy

14.28%

Upside

Reiterated

04/17/25

UBS reiterates Buy Rating on Abbott Labs (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

04/17/25

Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating

Patrick WoodMorgan Stanley

Morgan Stanley

CHF95.76→CHF103.95

Hold

-1.94%

Downside

Reiterated

04/17/25

Abbott price target raised to $127 from $117 at Morgan StanleyAbbott price target raised to $127 from $117 at Morgan Stanley

Matthew TaylorJefferies

Jefferies

CHF110.49→CHF112.13

Hold

5.78%

Upside

Reiterated

04/16/25

Abbott price target raised to $137 from $135 at JefferiesAbbott price target raised to $137 from $135 at Jefferies

Robbie MarcusJ.P. Morgan

J.P. Morgan

CHF114.59

Buy

8.10%

Upside

Reiterated

04/16/25

JPMorgan reiterates Overweight Rating on Abbott Labs (ABT)JPMorgan analyst Robbie Marcus reiterated an Overweight rating and $135.00 price target on Abbott Labs (NYSE: ABT).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Suraj KaliaOppenheimer

Oppenheimer

CHF114.59

Buy

8.10%

Upside

Reiterated

06/18/25

Abbott Laboratories (ABT) Gets a Buy from Oppenheimer

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

06/18/25

Citi Keeps Their Buy Rating on Abbott Laboratories (ABT)

Mike KratkyLeerink Partners

Leerink Partners

CHF117.04

Hold

10.42%

Upside

Initiated

06/16/25

Abbott Laboratories (ABT) Receives a Hold from Leerink Partners

Larry BiegelsenWells Fargo

Wells Fargo

CHF120.32

Buy

13.51%

Upside

Reiterated

06/09/25

Wells Fargo Remains a Buy on Abbott Laboratories (ABT)

Josh JenningsTD Cowen

TD Cowen

CHF118.68

Buy

11.96%

Upside

Reiterated

06/09/25

TD Cowen Remains a Buy on Abbott Laboratories (ABT)

Rick WiseStifel Nicolaus

Stifel Nicolaus

CHF110.49→CHF118.68

Buy

11.96%

Upside

Reiterated

05/27/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)

Matt MiksicBarclays

Barclays

CHF130.14

Buy

22.77%

Upside

Reiterated

05/20/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Alcon (NYSE: ALC)

David ToungArgus Research

Argus Research

CHF122.77

Buy

15.82%

Upside

Reiterated

04/21/25

Argus Research Remains a Buy on Abbott Laboratories (ABT)

Jayson BedfordRaymond James

Raymond James

CHF108.04→CHF116.22

Buy

9.64%

Upside

Reiterated

04/17/25

Abbott price target raised to $142 from $132 at Raymond JamesAbbott price target raised to $142 from $132 at Raymond James

Adam MaederPiper Sandler

Piper Sandler

CHF108.86→CHF118.68

Buy

11.96%

Upside

Reiterated

04/17/25

Abbott price target raised to $145 from $133 at Piper SandlerAbbott price target raised to $145 from $133 at Piper Sandler

Danielle AntalffyUBS

UBS

CHF121.13

Buy

14.28%

Upside

Reiterated

04/17/25

UBS reiterates Buy Rating on Abbott Labs (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

04/17/25

Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating

Patrick WoodMorgan Stanley

Morgan Stanley

CHF95.76→CHF103.95

Hold

-1.94%

Downside

Reiterated

04/17/25

Abbott price target raised to $127 from $117 at Morgan StanleyAbbott price target raised to $127 from $117 at Morgan Stanley

Matthew TaylorJefferies

Jefferies

CHF110.49→CHF112.13

Hold

5.78%

Upside

Reiterated

04/16/25

Abbott price target raised to $137 from $135 at JefferiesAbbott price target raised to $137 from $135 at Jefferies

Robbie MarcusJ.P. Morgan

J.P. Morgan

CHF114.59

Buy

8.10%

Upside

Reiterated

04/16/25

JPMorgan reiterates Overweight Rating on Abbott Labs (ABT)JPMorgan analyst Robbie Marcus reiterated an Overweight rating and $135.00 price target on Abbott Labs (NYSE: ABT).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

1 Month

xxx

Success Rate

19/27 ratings generated profit

Average Return

+1.17%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.37% of your transactions generating a profit, with an average return of +1.17% per trade.

3 Months

xxx

Success Rate

23/27 ratings generated profit

Average Return

+5.38%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.19% of your transactions generating a profit, with an average return of +5.38% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

24/25 ratings generated profit

Average Return

+18.68%

reiterated a buy rating last month

Copying Rick Wise's trades and holding each position for 1 Year would result in 92.00% of your transactions generating a profit, with an average return of +18.68% per trade.

2 Years

xxx

Success Rate

23/27 ratings generated profit

Average Return

+17.28%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.19% of your transactions generating a profit, with an average return of +17.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABT has received 37 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 114.72.

Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is CHF1.01 with a range of CHF0.99 to CHF1.03. The previous quarter’s EPS was CHF0.88. ABT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is CHF8.88B with a range of CHF8.83B to CHF8.99B. The previous quarter’s sales results were CHF8.32B. ABT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Stock Forecast FAQ

What is CH:ABT’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 114.72.

What is CH:ABT’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 8.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Abbott Laboratories a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy, which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s share price target?

The average share price target for Abbott Laboratories is 114.72. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF127.32 ,and the lowest forecast is CHF101.70. The average share price target represents 8.22% Increase from the current price of CHF106.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Abbott Laboratories?

To buy shares of CH:ABT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Abbott Laboratories (ABT) Stock Forecast & Price Target

ABT Analyst Ratings

ABT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABT Analyst Recommendation Trends

ABT Financial Forecast

ABT Earnings Forecast

ABT Sales Forecast

ABT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts